newsfilter
← Latest News
Business Wire·

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study